- Home
- CLSK vs SDGR Comparison
CLSK vs SDGR Comparison
Compare CLSK & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLSK
- SDGR
- Stock Information
- Founded
- CLSK 1987
- SDGR 1990
- Country
- CLSK United States
- SDGR United States
- Employees
- CLSK N/A
- SDGR N/A
- Industry
- CLSK Finance: Consumer Services
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- CLSK Finance
- SDGR Health Care
- Exchange
- CLSK Nasdaq
- SDGR Nasdaq
- Market Cap
- CLSK 2.2B
- SDGR 1.8B
- IPO Year
- CLSK N/A
- SDGR 2020
- Fundamental
- Price
- CLSK $7.69
- SDGR $21.93
- Analyst Decision
- CLSK Strong Buy
- SDGR Buy
- Analyst Count
- CLSK 9
- SDGR 7
- Target Price
- CLSK $21.75
- SDGR $32.29
- AVG Volume (30 Days)
- CLSK 22.6M
- SDGR 1.1M
- Earning Date
- CLSK 05-08-2025
- SDGR 04-30-2025
- Dividend Yield
- CLSK N/A
- SDGR N/A
- EPS Growth
- CLSK N/A
- SDGR N/A
- EPS
- CLSK 0.27
- SDGR N/A
- Revenue
- CLSK $467,488,000.00
- SDGR $207,539,000.00
- Revenue This Year
- CLSK $146.07
- SDGR $28.69
- Revenue Next Year
- CLSK $38.23
- SDGR $14.95
- P/E Ratio
- CLSK $28.15
- SDGR N/A
- Revenue Growth
- CLSK 118.07
- SDGR N/A
- 52 Week Low
- CLSK $7.22
- SDGR $16.67
- 52 Week High
- CLSK $24.72
- SDGR $29.15
- Technical
- Relative Strength Index (RSI)
- CLSK 38.46
- SDGR 47.81
- Support Level
- CLSK $7.46
- SDGR $19.48
- Resistance Level
- CLSK $8.61
- SDGR $21.90
- Average True Range (ATR)
- CLSK 0.82
- SDGR 1.65
- MACD
- CLSK 0.02
- SDGR -0.04
- Stochastic Oscillator
- CLSK 23.04
- SDGR 51.20
About CLSK CleanSpark Inc.
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.